[6] In 2023, it was the 63rd most commonly prescribed medication in the United States, with more than 10 million prescriptions
Compounding is an important alternative that can help resolve shortages and provide alternatives for patients who need personalized dosages, ingredients, or who need the removal of allergens
Ethics, scope, and intended research-only use Consistent with its existing catalog policies, Umbrella Labs reiterates that all Retatrutide-related materials and research outputs are intended strictly for non-clinical laboratory use and must not be interpreted as guidance for human administration, clinical protocols, or therapeutic decision-making
Sn phm l thc phm chc nng, khng thay th ch n ung cn bng
It is classified as a triple incretin receptor agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously